Author Topic: (Abst.) Tysabri's effect on disease progression in SPMS  (Read 51 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8244
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Tysabri's effect on disease progression in SPMS
« on: March 14, 2018, 06:28:54 am »
From The Lancet Neurology (March 12, 2018).This study was funded by Biogen. It shows that Tysabri didn't change the EDSS score for persons with SPMS but did improve arm functioning somewhat, using the 9-hole peg test:


Quote
No treatment effect was observed on the EDSS (OR 106, 95% CI 074153; nominal p=0753) or the T25FW (098, 074130; nominal p=0914) components of the primary outcome. However, natalizumab treatment reduced 9HPT [9-hole peg test] progression (OR 056, 95% CI 040080; nominal p=0001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab.



http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30069-3/fulltext
« Last Edit: March 14, 2018, 06:30:47 am by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
85 Views
Last post March 23, 2016, 03:35:11 pm
by agate
0 Replies
65 Views
Last post April 22, 2016, 05:14:05 pm
by agate
0 Replies
84 Views
Last post August 11, 2017, 08:12:48 am
by agate
0 Replies
38 Views
Last post November 16, 2017, 04:11:14 pm
by agate
0 Replies
39 Views
Last post June 08, 2019, 09:32:13 am
by agate